FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * ARMISTICE CAPITAL, LLC							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director Officer (give title below) _X_ Other (specify below)				
(Last) (First) (Middle) 510 MADISON AVENUE, 7TH FLOOR			on (N	Ionth/Day	/Year)						
(Street) NEW YORK, NY 10022			inal F	Filed(Month	/Day/Yea	6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person					
(7in)											
Date	Execution Date, if	Code (Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D)	Beneficially Owned Following Reported Transaction(s)	Ownership Form:	7. Nature of Indirect Beneficial Ownership		
		Code	v	Amount	(A) or (D)	Price	(ansar 5 and 1)	or Indirect (I) (Instr. 4)	(Instr. 4)		
12/10/2018		Р		50,000	A	\$ 0.3921	17,212,500	D (1)			
12/10/2018		P		0	A	\$ 0	17,212,500	I	See Footnote		
12/10/2018		P		0	A	\$ 0	17,212,500	I	See Footnote		
12/10/2018		Р		19,400	A	\$ 0.4056	17,231,900	D (1)			
12/10/2018		P		0	A	\$ 0	17,231,900	I	See Footnote		
12/10/2018		P		0	A	\$ 0	17,231,900	I	See Footnote		
12/11/2018		Р		6,800	A	\$ 0.4213	17,238,700	D (1)			
12/11/2018		P		0	A	\$ 0	17,238,700	I	See Footnote		
12/11/2018		P		0	A	\$ 0	17,238,700	I	See Footnote		
12/11/2018		P		24,153	A	\$ 0.4131	17,262,853	D (1)			
12/11/2018		P		0	A	\$ 0	17,262,853	I	See Footnote		
12/11/2018		Р		0	A	\$ 0	17,262,853	I	See Footnote		
	(Middle) TH FLOOR (Zip) 2. Transaction Date (Month/Day/Year) 12/10/2018 12/10/2018 12/10/2018 12/10/2018 12/10/2018 12/11/2018 12/11/2018 12/11/2018 12/11/2018 12/11/2018	EYEGATE PF [EYEG] 3. Date of Earliest 12/10/2018 4. If Amendment, (Zip) Ta 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 12/10/2018 12/10/2018 12/10/2018 12/10/2018 12/11/2018 12/11/2018 12/11/2018 12/11/2018 12/11/2018 12/11/2018 12/11/2018	EYEGATE PHARMA([EYEG] 3. Date of Earliest Transaction 12/10/2018 4. If Amendment, Date Original Properties (Month/Day/Year) 2A. Deemed Execution Date, if (Month/Day/Year) Code (Instr. 8) Code (Instr. 8) P	EYEGATE PHARMACEU	EYEGATE PHARMACEUTICAL [EYEG] 3. Date of Earliest Transaction (Month/Day 12/10/2018 4. If Amendment, Date Original Filed(Month 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. A. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (A) or Di (Instr. 3) Code (Instr. 8) (Instr. 3) Code (Instr. 3) P 0 12/10/2018 P 0 12/10/2018 P 19,400 12/10/2018 P 0 12/10/2018 P 0 12/10/2018 P 0 12/11/2018 P 0	EYEGATE PHARMACEUTICALS INCO EYEG] 3. Date of Earliest Transaction (Month/Day/Year) 12/10/2018 4. If Amendment, Date Original Filed(Month/Day/Year) 12/10/2018 3. Transaction 2. Transaction Date 2. Transaction 2. T	EYEGATE PHARMACEUTICALS INC [EYEG]	EVEGATE PHARMACEUTICALS INC [EYEG] 3. Date of Earliest Transaction (Month/Day/Year) 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing, Tomn filed by More than One Reporting Form filed by More fall b	EYEGATE PHARMACEUTICALS INC [EYEG]		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Security (Instr. 3)	Conversion	Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	of Deriv Secur Acqu (A) of Dispo of (D) (Instr	rative rities ired rosed) . 3,	and Expiration Date (Month/Day/Year)		Amount of Underlying		Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial
				Code	(A)	,	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
ARMISTICE CAPITAL, LLC 510 MADISON AVENUE 7TH FLOOR NEW YORK, NY 10022	X	X						
Armistice Capital Master Fund Ltd. C/O DMS CORPORATE SERVICES LTD. 20 GENESIS CLOSE, P.O. BOX 314 GRAND CAYMAN, E9 KY1-1104		X						
Boyd Steven C/O ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10022	X	X						

Signatures

Armistice Capital, LLC, By: /s/ Steven Boyd, Managing Member	12/12/2018
**Signature of Reporting Person	Date
Armistice Capital Master Fund Ltd., By: /s/ Steven Boyd, Director	12/12/2018
**Signature of Reporting Person	Date
By: /s/ Steven Boyd	12/12/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported securities are directly owned by Armistice Capital Master Fund Ltd.
 - The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd. The reported securities may also be deemed to be indirectly beneficially owned by
- (2) Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund Ltd. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.